Literature DB >> 8813428

Childhood leukemia following phototherapy for neonatal hyperbilirubinemia (Denmark).

J H Olsen1, H Hertz, S K Kjaer, A Bautz, L Mellemkjaer, J D Boice.   

Abstract

To test the hypothesis that exposure to high intensity lightning (around 400 nanometers) in neonatal nurseries increases the incidence of childhood leukemia, over 55,120 newborn children treated with phototherapy for hyperbilirubinemia were identified from the Danish Hospital Discharge Register for 1977-89. Linkage of the roster with the national cancer registry through 1991 revealed 87 childhood cancers, whereas 85 were expected from the rates for the general population. The incidence of leukemia in 34 children was not unusual (standardized incidence ratio [SIR] = 1.2, 95 percent confidence interval [CI] = 0.8-1.7). Subgroup analyses revealed no remarkable patterns for any category of leukemia subtype, gender, or age at diagnosis. We conclude that whole-body exposure to phototherapy (420-470 nm) shortly after birth is not a significant risk factor for childhood leukemia.

Entities:  

Mesh:

Year:  1996        PMID: 8813428     DOI: 10.1007/bf00052666

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  9 in total

1.  Childhood leukemia and neonatal exposure to lighting in nurseries.

Authors:  R W Miller
Journal:  Cancer Causes Control       Date:  1992-11       Impact factor: 2.506

2.  Superoxide formation by protoporphyrin as seen by spin trapping.

Authors:  G R Buettner; L W Oberley
Journal:  FEBS Lett       Date:  1979-02-01       Impact factor: 4.124

3.  Predominance of hospital deliveries among children with acute lymphocytic leukemia: speculations about neonatal exposure to fluorescent light.

Authors:  H A van Steensel-Moll; C M van Duijn; H A Valkenburg; G E van Zanen
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

Review 4.  Photobiology of porphyrins.

Authors:  J D Spikes
Journal:  Prog Clin Biol Res       Date:  1984

5.  Neonatal exposure to protoporphyrin-activating lighting as a contributing cause of childhood acute lymphocytic leukemia.

Authors:  S A Ben-Sasson; D L Davis
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

6.  Incidence of childhood cancer in Denmark 1943-1984.

Authors:  P de Nully Brown; H Hertz; J H Olsen; M Yssing; E Scheibel; O M Jensen
Journal:  Int J Epidemiol       Date:  1989-09       Impact factor: 7.196

7.  Cancer registration in Denmark and the study of multiple primary cancers, 1943-80.

Authors:  O M Jensen; H H Storm; H S Jensen
Journal:  Natl Cancer Inst Monogr       Date:  1985-12

8.  Residence near high voltage facilities and risk of cancer in children.

Authors:  J H Olsen; A Nielsen; G Schulgen
Journal:  BMJ       Date:  1993-10-09

9.  Photodynamic action and chromosomal damage: a comparison of haematoporphyrin derivative (HpD) and light with X-irradiation.

Authors:  J F Evensen; J Moan
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

  9 in total
  4 in total

Review 1.  Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer.

Authors:  Frank Corbin
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

3.  An Increased Genotoxic Risk in Lymphocytes from Phototherapy-Treated Hyperbilirubinemic Neonates.

Authors:  Seyed Alireza Mesbah-Namin; Maryam Shahidi; Maryam Nakhshab
Journal:  Iran Biomed J       Date:  2017-04-29

4.  Is neonatal phototherapy associated with a greater risk of childhood cancers?

Authors:  Fatemeh Sabzevari; Reza Sinaei; Bahareh Bahmanbijari; Simin Dehghan Krooki; Azam Dehghani
Journal:  BMC Pediatr       Date:  2022-06-22       Impact factor: 2.567

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.